Mutations in the FAT1 and RB1 tumor suppressors, potentially associated with resistance to CDK4/6 inhibitors (Li et al., 2018), were also observed in 10% and 4% of IBC, respectively. Here, CDK4 is linked to inflammatory breast carcinoma.